FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe response	8)									-					
1. Name and Address of Reporting Person * EVNIN LUKE					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE, 31ST FLOOR				3. Date of Earl 06/22/2004	3. Date of Earliest Transaction (Month/Day/Year) 06/22/2004						Office	er (give title belo	ow)	Other (specify	below)	
BOSTON, MA 02199				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting Person						
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui						uired, Disp	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		if C	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Form:	7. Nature of Indirect Beneficial			
				(Month/Day/Yea	ar)	Code	V	Amount	(A) or (D)	Price	(Instr. 3	and 4)		Direct (D) or Indirect (I) (Instr. 4)		
Common Stock		06/22/2004			S		29,805 (1)	D	\$ 15.50	3,461,	461,158		I	See Footnote		
Common Stock		06/23/2004			S		388 (3)	D	\$ 15.5	3,460,	3,460,770		I	See Footnote		
Reminder:	Report on a s	separate line	for each class of sec	Derivative Secu	ıritie	s Acqu	Pe co th	ersons whentained in the form dinger Disposed	no res n this splays	form a s a curr Benefici	re not requently valid	OMB con	formation spond unle trol numbe	ess	C 1474 (9-02)	
1 Tid C	1	2	24 D									0 D.:C	0 N1	-£ 10	11	
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	3. Transacti Date (Month/Day	Execution Dany	4. date, if Transacti Code (Instr. 8)	0 E S A (A E 0 (I	lumber	ar (N	and Expiration Date (Month/Day/Year) (Month/Day/Year) S (4		te Ai Ui Se	Title and nount of iderlying curities str. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owner Form of Deriva Securi Direct or Indi	Beneficial Ownersh (Instr. 4) (D) rect	
				Code	V ((A) (I	E	ate xercisable	Expira Date	ation Ti	Amount or Number of Shares					

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
EVNIN LUKE C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVENUE, 31ST FLOOR BOSTON, MA 02199		X				
GADICKE ANSBERT C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVENUE, 31ST FLOOR BOSTON, MA 02199		X				

Signatures

/s/ Luke Evnin	06/23/2004
**Signature of Reporting Person	Date
/s/ Ansbert Gadicke	06/23/2004
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- See Form 4 filed for MPM BioVentures III-QP, L.P. for additional members of this joint filing. The shares were sold as follows: 1,668 by MPM BioVentures III, L.P. ("BVIII"); 24,810 by MPM BioVentures III-QP, L.P. ("BVIII QP"); 2,097 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BVIII KG"); 749 by MPM Bioventures III Parallel Fund, L.P. ("BVIII PF"); and 481 MPM Asset Management Investors 2003 BVIII LLC ("BVAM LLC"). MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures III LLC ("BVIII LLC") are the direct and indirect partners of BVIII, BVIII QP, BVIII PF and BVIII KG.
- The shares are held as follows: 193,721 BVIII; 2,881,147 by BVIII QP; 243,492 by BVIII KG; 87,015 by BVIII PF; and 55,783 by BVAM LLC. Luke Evnin, Ansbert (2) Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon, III, Michael Steinmetz and Kurt Wheeler are the members of BVIII LLC and BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (3) The shares were sold as follows: 22 by BVIII; 323 by BVIII QP; 27 by BVIII KG; 10 by BVIII PF; and 6 by BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (4) The shares are held as follows: 193,699 by BVIII; 2,880,824 by BVIII QP; 243,465 by BVIII KG; 87,005 by BVIII PF; and 55,777 by BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.